Andere talen Sight Sciences, Inc.

Aandelen

SGHT

US82657M1053

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
6,085 ^USD	-1,38%		-4,92%	+17,93%

28/05	Sight Sciences, Inc. Kondigt de publicatie aan van een nieuwe analyse van de ROMEO-studie waaruit blijkt dat Omni®? bij mild, matig en gevorderd glaucoom	CI
14/05	Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Sight Sciences Announces the Release of its First Sustainability Report	10/06
Sight Sciences Announces Publication of a New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI across Mild, Moderate, and Advanced Glaucoma	29/05
Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis	28/05
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis	28/05
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma	28/05
Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma	28/05
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference	07/05
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed	03/05
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M	02/05
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance	02/05
Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024	02/05
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Sector Update: Health Care Stocks Edge Higher Late Afternoon	29/04
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading	29/04
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	29/04
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump	29/04
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery	29/04
Sight Sciences : SGHT Proxy - Apr'24	26/04
Sight Sciences to Report First Quarter Financial Results on May 2, 2024	18/04
GNW-Adhoc: Sight Sciences gibt die Veröffentlichung einer groß angelegten, praxisnahen MIGS-Studie als Nachweis für die Wirksamkeit des umfassenden Verfahrens zur Wiederherstellung des Kammerwasserabflusses mit der OMNI® Surgical System-Technologie sowohl bei der Senkung des Augeninnendrucks als auch bei der Einnahme von Medikamenten zur Senkung des Augeninnendrucks über einen Zeitraum von 2 Jahren bei Patienten mit Glaukom bekannt	12/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Sight Sciences, Inc.

Aandelen

SGHT

US82657M1053

Andere talen

Filters